Heterogeneity in cancer guidelines: should we eradicate or tolerate?
G. Pentheroudakis(University Hospital of Ioannina), Nikolaos Pavlidis(University Hospital of Ioannina), Henrik Hansen(University of Antwerp), Rolf A. Stahel(International Breast Cancer Study Group)
Cited by 56
Related Papers
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
|The Lancet Oncology|2022|738
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577
ESMO Guidance for Reporting Oncology real-World evidence (GROW)
|Annals of Oncology|2023|209
Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2010|166
Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)
|Leukemia & lymphoma/Leukemia and lymphoma|2006|160